Stock Events

Stock Events

Hepion Pharmaceuticals 

$0
27
-$0-31.58% Monday 21:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
10
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-95
-64.53
-34.07
-3.6
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-48.93MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CTRVP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a leading biopharmaceutical company that develops and markets drugs for life-threatening illnesses including liver disease, a key area of focus for Hepion Pharmaceuticals.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating treatments for serious diseases, including liver diseases, which puts it in direct competition with Hepion Pharmaceuticals' efforts in NASH and liver-related treatments.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals focuses on the development of novel therapies for cardiovascular, metabolic, and liver diseases, including NASH, making it a competitor in Hepion's market space.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, positioning it as a competitor to Hepion Pharmaceuticals in the NASH treatment market.
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
Galmed Pharmaceuticals is engaged in the development of oral therapies for the treatment of liver diseases, including NASH, competing with Hepion Pharmaceuticals in the liver disease therapeutic area.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including metabolic and liver-related diseases, making it a competitor in the broader market for liver disease treatments.
Enanta Pharmaceuticals
ENTA
Mkt Cap312.19M
Enanta Pharmaceuticals is focused on creating treatments for liver diseases and respiratory infections, with a significant focus on liver diseases, making it a competitor to Hepion.
FibroGen
FGEN
Mkt Cap44.97M
FibroGen develops therapies for the treatment of anemia, fibrosis, and cancer, with its work on fibrosis making it a competitor in the space of liver disease treatment, including areas targeted by Hepion Pharmaceuticals.

About

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Show more...
CEO
Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.
Employees
13
Country
US
ISIN
US4268972035

Listings

OTC Link
US
HEPA
OTC Link
US
CTRVP

0 Comments

Share your thoughts

FAQ

What is Hepion Pharmaceuticals stock price today?▼
The current price of CTRVP is $0 USD — it has decreased by -31.58% in the past 24 hours. Watch Hepion Pharmaceuticals stock price performance more closely on the chart.
What is Hepion Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Hepion Pharmaceuticals stocks are traded under the ticker CTRVP.
When is the next Hepion Pharmaceuticals earnings date?▼
Hepion Pharmaceuticals is going to release the next earnings report on February 25, 2026.
What is Hepion Pharmaceuticals revenue for the last year?▼
Hepion Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Hepion Pharmaceuticals net income for the last year?▼
CTRVP net income for the last year is -48.93M USD.
How many employees does Hepion Pharmaceuticals have?▼
As of February 03, 2026, the company has 13 employees.
In which sector is Hepion Pharmaceuticals located?▼
Hepion Pharmaceuticals operates in the Healthcare sector.
When did Hepion Pharmaceuticals complete a stock split?▼
The last stock split for Hepion Pharmaceuticals was on May 11, 2023 with a ratio of 1:20.
Where is Hepion Pharmaceuticals headquartered?▼
Hepion Pharmaceuticals is headquartered in Edison, US.